Under President Trump, the U.S. Patent and Trademark Office has sought to encourage the issuance of more patents and limit the ability to challenge them in post-grant proceedings; since John Squires ...

When someone creates a US patent, they go through a review process to stop the most blatant copies from previous patents or pre-existing work. After this, you may still have bad patents get through, ...

Unified Patents is paid by its members to fight against non-practicing entity (NPE) patent assertions — often by challenge patent validity via inter partes review. In this case, Unified challenged ...

When should a brand company expect generic companies to file inter partes review petitions, seeking to invalidate a patent, and how should the brand company handle it? When the Delaware district court ...

In a February 10, 2025 order, the Federal Circuit Court of Appeals rejected the application of the collateral estoppel doctrine to patent claims asserted in a district court infringement action where ...

“Inter partes review is a primary tool used by defendants in litigation to invalidate patents, and the Director has helped to guard against its overreach. However, there is nothing to stop a future ...

ST. LOUIS--(BUSINESS WIRE)--Geneoscopy, Inc., a life sciences company focused on developing diagnostic tests for the advancement of gastrointestinal health, today announced that the U.S. Patent Trial ...

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up for any (or all) of our 25+ Newsletters. Some states have laws and ethical rules regarding solicitation and ...

Inter partes review (IPR) is an extremely effective alternative or supplement to litigation, and there are appreciable benefits to challenging an issued patent in an IPR rather than before a federal ...

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up for any (or all) of our 25+ Newsletters. Some states have laws and ethical rules regarding solicitation and ...

Thanks to Congress’ administrative alternative to court litigation of patents, generic drug manufacturers have embraced a new process, known as inter partes review (IPR), and successfully challenged ...

We study the determinants of patent “quality”—the likelihood that an issued patent can survive a post-grant validity challenge. We do so by taking advantage of two recent developments in the U.S.